
In this article 12 sections
- What the 2026 data say about CNS demand
- Why neuro-psychiatry suits the franchise model
- The main product groups in a neuro-psychiatry range
- Compliance needs extra care in this speciality
- Who prescribes neuro-psychiatry products
- Choosing a neuro-psychiatry PCD company
- Working with chemists in a sensitive speciality
- Your own neuro brand through third-party manufacturing
- A sample neuro-psychiatry bag for a district partner
- Common mistakes in neuro-psychiatry franchises
- Frequently Asked Questions
- Start Your Neuro-Psychiatry Franchise with the Right Company
Neuro-psychiatry used to be a speciality that franchise partners avoided. Few psychiatrists outside big cities, patients who hid their prescriptions, controlled drugs with extra paperwork and doctors who were hard to see. That picture has changed a lot. More patients now walk into clinics asking about anxiety, sleep and depression, neurologists and psychiatrists have opened practices in district towns, and general physicians prescribe more for neuropathic pain, vertigo and sleep than they did a few years ago.
The numbers in 2026 back this up. For partners looking for a chronic speciality with steady repeat prescriptions, a neuro-psychiatry PCD pharma range is worth a serious look. This guide covers the market data, the main product groups, the extra compliance care the speciality needs, and how to build prescriptions responsibly.
What the 2026 data say about CNS demand
Pharmarack's analysis of the neuro and CNS segment, published by BioSpectrum India in February 2026, put the segment at Rs 16,139 crore in December 2025, growing 9 per cent in value with 2 per cent volume growth. CNS contributed 11 per cent of the market's growth. Anti-epileptics were the biggest sub-group at Rs 4,693 crore, 29 per cent of CNS, growing 12 per cent. Antidepressants and mood disorder drugs were about Rs 2,663 crore, neuropathic pain about Rs 2,414 crore, atypical antipsychotics about Rs 1,089 crore growing 12 per cent, and anti-vertigo about Rs 955 crore. Sheetal Sapale of Pharmarack said 2026 was expected to see sustained double-digit momentum in select CNS sub-segments.
The momentum held through the year. Pharmarack's August 2026 figures, reported by BioSpectrum India, showed neuro and CNS at about Rs 1,542 crore for the month, with value growth of 11.3 per cent and unit growth of 1.5 per cent. The mid-year forecast had projected neurology and CNS to grow about 12.3 per cent for calendar 2026.
Inside the antidepressant market
A summary of PharmaTrac data to September 2026, published by Omnicuris MedShots, put the antidepressant market at over Rs 2,842 crore, up 8.63 per cent in value over twelve months, while unit volume dipped slightly. It noted strong growth for sertraline and desvenlafaxine, and said escitalopram with clonazepam combinations made up roughly a quarter of the market.
The same summary flagged a practical problem doctors face: many patients stop antidepressants too early. For a franchise partner, that is important. In psychiatry, a brand that patients can afford and keep taking for months is worth more than a premium brand they abandon after the first strip.
Why neuro-psychiatry suits the franchise model
Three things make this speciality attractive. First, it is chronic. Epilepsy, depression, anxiety disorders, Parkinson's disease, migraine prophylaxis and neuropathic pain all need months or years of treatment, which means steady monthly orders. Second, prescriber loyalty is strong. Neurologists and psychiatrists tend to stick with brands that work for their patients and that are reliably available. Third, the prescriber base is spreading. In many tier-2 cities and district towns there are now a few psychiatrists and neurologists, along with general physicians and diabetologists who treat neuropathy, sleep problems and mild anxiety.
The flip side is that neuro-psychiatry needs more care than most specialities: controlled substances, stricter record-keeping, and a duty not to promote medicines in ways that encourage misuse. Partners who respect that do well. Those who treat it like a general range get into trouble.
The main product groups in a neuro-psychiatry range
A good neuro-psychiatry bag covers the conditions that bring most patients to neurologists, psychiatrists and the physicians who share their work. Here is how the main groups fit together.
Anti-epileptics
As the biggest CNS sub-group, anti-epileptics are the anchor of most neuro ranges. Levetiracetam, sodium valproate and divalproex, carbamazepine and oxcarbazepine, lamotrigine, lacosamide, clobazam and topiramate are commonly prescribed. Epilepsy patients need uninterrupted supply. A missed refill can mean a seizure, so availability matters more here than in almost any other group. Choose a company with a reliable tablets range and a history of steady supply, and check quality carefully. Levetiracetam products have appeared in 2026 drug alerts, so ask your company for certificates of analysis and the plant name for each anti-epileptic you sell.
Antidepressants and anti-anxiety medicines
Escitalopram, sertraline, fluoxetine, paroxetine, desvenlafaxine, duloxetine, mirtazapine and amitriptyline are the core. Combinations with clonazepam are widely prescribed for short periods in anxiety with depression. Remember that benzodiazepines such as clonazepam and alprazolam are Schedule H1 drugs, with stricter record-keeping requirements at the chemist and wholesale level. Your stockists and chemists must maintain the required registers, and your own records should be complete and traceable.
Antipsychotics and mood stabilisers
Olanzapine, risperidone, quetiapine, aripiprazole and newer agents, along with lithium and valproate as mood stabilisers, are prescribed mainly by psychiatrists. This is a smaller, specialist-driven group, but prescriptions are long-term and loyal.
Neuropathic pain and vitamin support
Pregabalin and gabapentin, often combined with methylcobalamin, and nortriptyline or duloxetine for neuropathic pain, are prescribed not only by neurologists but by diabetologists, orthopaedicians and general physicians. This gives the neuro range a much wider prescriber base. It also overlaps neatly with a cardiac and diabetic range, since diabetic neuropathy is common, and with ortho, which we discussed in our ortho and pain franchise guide. Pregabalin has a known misuse risk in some regions, so promote it strictly for its approved uses.
Migraine, vertigo and sleep
Migraine prophylaxis with flunarizine, propranolol or topiramate, acute treatment with triptans and naproxen combinations, betahistine and cinnarizine for vertigo, and melatonin-based products for sleep are common in general practice as well as neurology. These are good products for broadening your reach beyond specialists.
Parkinson's, dementia and stroke care
Levodopa with carbidopa, pramipexole, ropinirole, donepezil, memantine and citicoline are used in older patients. As the population ages, this group grows steadily, and Pharmarack's data showed anti-Parkinson products growing in double digits at the end of 2025.
Supportive nutraceuticals
Methylcobalamin, alpha-lipoic acid, omega-3 and magnesium-based products are often prescribed alongside neuro medicines. A small nutraceutical add-on can complement the main range, and capsules and softgels from a good capsules range suit many of them.
Compliance needs extra care in this speciality
Neuro-psychiatry includes several drugs with abuse potential, and regulators watch the channel closely. Getting this right protects your licence and your reputation.
Know your schedules. Benzodiazepines and some other CNS drugs fall under Schedule H1, which requires chemists to record prescriber, patient and quantity details, and keep those records for inspection. Some drugs fall under narcotics and psychotropic substances rules and need additional licences to handle. Ask your company exactly which products in its list fall under which schedule, and whether you need any extra licence to stock them.
Sell only to licensed buyers. Supply only to licensed chemists and stockists, with proper invoices. Never sell neuro products to unlicensed outlets or individuals, however large the order.
Keep complete records. Batch-wise purchase and sale records are always required, but in this speciality inspectors are more likely to check them. Keep them clean and current.
Promote responsibly. Do not promote sedatives or pregabalin for unapproved uses, and never position them as lifestyle products. Follow the Uniform Code for Pharmaceutical Marketing Practices 2024, which we covered in our article on Revised Schedule M and UCPMP.
Who prescribes neuro-psychiatry products
A franchise partner who only chases psychiatrists will find the speciality slow. One who maps all the prescribers who write CNS drugs will find it surprisingly broad.
Neurologists drive anti-epileptics, Parkinson's, migraine and stroke care. Even in tier-2 cities there are now a few, often attached to multi-speciality hospitals.
Psychiatrists drive antidepressants, antipsychotics and mood stabilisers. They are fewer, but their patients stay on treatment for long periods.
General physicians and consultant physicians write a large share of anxiety, sleep, vertigo and neuropathic pain prescriptions, especially in smaller towns where specialists are scarce.
Diabetologists are major prescribers of pregabalin and methylcobalamin combinations for diabetic neuropathy.
Orthopaedicians and spine specialists prescribe neuropathic pain products for radiculopathy and back pain.
Paediatricians and paediatric neurologists treat childhood epilepsy and ADHD in larger centres.
Map each of these groups in your territory before you choose your product list. A district town might have one psychiatrist, two neurologists, five diabetologists and fifty physicians. A bag built for that mix will lean on neuropathic pain, vertigo, sleep and anti-epileptics, with a smaller psychiatry list for the specialist. Our guide on territory planning and monopoly rights walks through how to size a territory for your team.
Detailing in this speciality
Neurologists and psychiatrists are evidence-driven. They want to know the plant, the bioequivalence or quality data where available, the strengths and release forms you offer, and whether supply will be reliable. Brief your representatives properly. A representative who can discuss titration, extended-release versus immediate-release forms and the patient's ability to afford long-term therapy earns far more respect than one who only talks margins.
Patient adherence is a real issue in psychiatry, as the Omnicuris summary noted. Practical support, such as clear patient leaflets in Hindi and local languages, calendar packs where appropriate, and affordable pricing for long-term therapy, helps doctors keep patients on treatment and keeps your prescriptions steady. Fair pricing matters here too, and we explained why in our post on fair MRP and ethical PCD franchise.
Choosing a neuro-psychiatry PCD company
Most CNS products in the franchise channel are made in the same clusters as other ranges: Baddi in Himachal Pradesh, Haridwar in Uttarakhand and the Ahmedabad belt in Gujarat. Many franchise companies are based in Chandigarh, Panchkula, Mohali and Ambala.
Because many CNS drugs have narrow dosing margins and patients take them for years, manufacturing quality matters even more than usual. Ask for the manufacturing licence copies listing the products, the plant's revised Schedule M or WHO-GMP status, recent certificates of analysis, and dissolution data for extended-release tablets. Check the plant name against the monthly alerts on cdsco.gov.in. Our guide on NSQ alerts and marketer responsibility explains what to look for.
Also ask the company how it handles Schedule H1 and other controlled products: which ones it sells, what documents it needs from you, and how it supports your stockists with record-keeping. A company that is casual about this is a risk to your licence.
Finally, ask for monopoly rights in writing, especially for the neuro division if the company has several. In a speciality with few specialists per district, another partner with the same brand can quickly take your doctors.
Apromart brings together top companies listed from PAN India, so you can compare several neuro ranges before you choose. Start with neuro-psychiatry PCD pharma companies and the wider speciality-wise PCD pharma companies directory.
Working with chemists in a sensitive speciality
Chemists play a bigger role in neuro-psychiatry than many partners realise. Patients on long-term antidepressants or anti-epileptics often refill at the same shop every month, and a chemist who has your brand in stock keeps that patient on it. A chemist who does not will substitute or send the patient elsewhere.
Two things matter most. The first is reliable supply, which we have already discussed. The second is respect for the chemist's compliance burden. Schedule H1 products mean extra registers and extra scrutiny for the shop. A partner who supplies clean invoices, correct batch details and products with clear labelling makes the chemist's job easier, and chemists remember that. Never pressure a chemist to sell controlled products without a prescription. Apart from being wrong, it puts both of you at risk.
Privacy matters too. Many patients are still uncomfortable being seen buying psychiatric medicines. Simple, discreet packaging and a chemist who handles prescriptions quietly help patients continue treatment. When you choose a company, look at its pack designs with this in mind.
It also helps to keep chemists informed when a product changes. If a strength is discontinued, a pack size changes or a batch is recalled, tell the chemists who stock it before the patient finds out at the counter. In a speciality where patients are anxious about any change to their medicine, a chemist who can explain calmly what has happened, and what the alternative is, saves the prescription. A short WhatsApp note from your representative to the main chemists, followed by a visit, is usually enough. Partners who do this consistently find that chemists start recommending their brands when a doctor writes a generic name.
Your own neuro brand through third-party manufacturing
Partners who build steady neuro prescriptions over two or three years sometimes want their own brand for their top products. This is possible, but it needs more care than an own brand in a general range. Extended-release tablets need a plant with proven formulation skill and dissolution testing. Controlled substances need the right manufacturing licences and record systems at the plant. And because doctors in this speciality are cautious, a new brand needs strong quality evidence to win prescriptions.
If you go this route, start with the simpler, high-volume products, such as pregabalin with methylcobalamin, levetiracetam, escitalopram or betahistine, and leave controlled and complex products for later. Compare plants on the tablet third-party manufacturers and capsule third-party manufacturers listings, and ask each plant for its experience with CNS products specifically. A plant that already makes these for established brands is a far safer starting point than one that has never made them.
Pricing in a chronic speciality
Long-term therapy changes how patients feel about price. A strip that costs a little more is easy to accept once. Paying it every month for two years is different. In neuro-psychiatry, affordable pricing directly improves adherence, and adherence directly improves your sales. Check which of your products fall under ceiling prices set by the NPPA, keep MRPs within those limits, and set the rest at levels a patient can sustain. A neurologist who sees patients staying on your brand month after month will keep writing it.
A sample neuro-psychiatry bag for a district partner
Consider a franchise partner in a city like Bareilly, Ujjain or Muzaffarpur, with two medical representatives. The prescriber base might include two neurologists, one or two psychiatrists, several diabetologists and many physicians. A focused starting bag could look like this.
For epilepsy: levetiracetam in two strengths, sodium valproate or divalproex extended-release, and clobazam. For depression and anxiety: escitalopram, sertraline and one escitalopram with clonazepam combination, handled with full Schedule H1 records. For neuropathic pain: pregabalin with methylcobalamin in two strengths, and duloxetine. For vertigo and migraine: betahistine and flunarizine. For older patients: citicoline, and if a neurologist in the area sees many Parkinson's patients, a levodopa with carbidopa product. For support: a methylcobalamin and alpha-lipoic acid capsule.
That is around fourteen to sixteen products. It gives the representative something for every prescriber on the map and keeps the psychiatry list focused. Expand into antipsychotics and newer agents once you have a psychiatrist who writes regularly.
Pairing with other ranges
Neuro works well alongside other chronic ranges. Partners who already carry a cardio-diabetic bag add neuropathic pain products naturally. Those with an ortho range can add pregabalin and methylcobalamin for spine patients. And a general range benefits from vertigo, sleep and anxiety products that physicians write every day. For the diabetes link, see our article on semaglutide generics and the cardio-diabetic opportunity.
Common mistakes in neuro-psychiatry franchises
The first is treating controlled drugs casually. Selling Schedule H1 products without proper records, or to outlets that do not keep them, can cost you your licence. Build compliance into your process from day one.
The second is stocking too many psychiatry products for too few psychiatrists. A district with one psychiatrist cannot support twenty psychiatric brands. Start with what your prescribers actually write.
The third is weak supply. Patients on anti-epileptics and antidepressants need every refill on time. Stockouts lose doctors quickly in this speciality, and they can hurt patients.
The fourth is pushing combinations or high doses for the margin. Psychiatrists notice, and regulators do too. Promote what the doctor needs for the patient in front of them.
The fifth is overlooking quality. Narrow therapeutic windows mean small differences in content or release can affect patients. Only work with companies whose plants and testing you have checked.
Frequently Asked Questions
Is neuro-psychiatry a good speciality for PCD franchise in 2026?
Yes, for partners who handle compliance well. Pharmarack data showed neuro and CNS growing 11.3 per cent in value in August 2026, and the segment was worth about Rs 16,139 crore in December 2025. It is a chronic speciality with long-term prescriptions and loyal prescribers.
Which products are most important in a neuro range?
Anti-epileptics are the largest CNS sub-group, followed by antidepressants and mood disorder drugs and neuropathic pain products. A practical range also includes vertigo, migraine, sleep, Parkinson's and dementia products, plus supportive nutraceuticals like methylcobalamin.
Do I need a special licence to sell neuro-psychiatry products?
You need a valid wholesale drug licence for all products. Benzodiazepines and some other CNS drugs fall under Schedule H1, which requires detailed records at the chemist and wholesale level, and some drugs fall under narcotics and psychotropic substances rules that may need additional licences. Ask your company which products fall under which rules.
Who prescribes neuro-psychiatry medicines apart from specialists?
General physicians, diabetologists, orthopaedicians and spine specialists prescribe many CNS products, especially for neuropathic pain, anxiety, sleep and vertigo. In smaller towns, physicians often write the majority of these prescriptions.
Which antidepressants are growing fastest?
A summary of PharmaTrac data to September 2026 reported strong growth for sertraline and desvenlafaxine, with escitalopram and clonazepam combinations making up roughly a quarter of the antidepressant market, which crossed Rs 2,842 crore.
How many products should a new neuro franchise start with?
Around fourteen to sixteen well-chosen products covering epilepsy, depression and anxiety, neuropathic pain, vertigo and migraine, and older patients' needs is a practical start for a district partner. Expand once your specialists prescribe regularly.
How do I check the quality of a neuro PCD company?
Ask for manufacturing licence copies listing the products, the plant's revised Schedule M or WHO-GMP status, recent certificates of analysis and dissolution data for extended-release tablets. Search CDSCO drug alerts for the plant name before you sign.
Can I get monopoly rights for a neuro division?
Many companies offer district monopoly for their neuro or CNS division. Get it in writing, with clear minimum orders, because a speciality with few specialists per district is easy for another partner to disrupt.
Start Your Neuro-Psychiatry Franchise with the Right Company
If you are ready to add a neuro-psychiatry range, Apromart can help you compare companies on products, quality and terms. Browse neuro-psychiatry PCD pharma companies and the PCD pharma franchise business opportunity listings, then post your requirement with your district and the doctors you cover. Verified companies will contact you with their ranges. For a second opinion on terms, contact the Apromart team.






